<DOC>
	<DOC>NCT01093807</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.</brief_summary>
	<brief_title>Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<criteria>Office Blood Pressure (BP): Sitting diastolic blood pressure (SDBP)100109 mmHg (inclusive) and sitting systolic blood pressure (SSBP) &lt; 180 mmHg after a 2 week placebo runin period Home Blood Pressure: diastolic blood pressure (DBP)at home â‰¥ 85 mmHg in the last week of the placebo runin period Normal Electrocardiogram (ECG), first degree Atrioventricular block or other changes not considered clinically significant Secondary or severe hypertension History of cerebro or cardiovascular complications Type 1 or Type 2 diabetes on drug treatment Severe renal or hepatic insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Lercanidipine</keyword>
	<keyword>Calcium antagonist</keyword>
	<keyword>Enalapril</keyword>
</DOC>